ANDA 79028, held by Watson Labs. Galantamine Hydrobromide.
As of Nov 15, 2026, ANDA 79028 (Galantamine Hydrobromide), held by Watson Labs, was first approved by FDA on Dec 15, 2008, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 15, 2008 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 8MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 16MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 24MG BASE · capsule, extended release;oral | Galantamine Hydrobromide | Rx |
| Jun 14, 2022 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jun 14, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jun 14, 2022 | Supplement 14Labeling · Standard review | Approved | None posted |
| Dec 14, 2017 | Supplement 10Labeling · Standard review | Approved | None posted |
| Dec 15, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters